Barclays analyst Gena Wang raised the firm’s price target on Zymeworks to $9 from $7 and keeps an Equal Weight rating on the shares after Jazz exercised the option to continue the zanidatamab collaboration with an additional $325M upfront payment to Zymeworks. The payment strengthens its financial position and supports Zymeworks’ earlier pipeline development, Wang tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZYME: